Estrogen: A Comprehensive Review of Synthesis, Signaling, and Implications in Health and Disease

Estrogen: A Comprehensive Review of Synthesis, Signaling, and Implications in Health and Disease

Many thanks to our sponsor Maggie who helped us prepare this research report.

Abstract

Estrogens are a group of steroid hormones primarily recognized for their critical role in female reproductive health. However, their influence extends far beyond reproduction, impacting a wide array of physiological processes including bone metabolism, cardiovascular function, neurological health, and immune modulation. This comprehensive review delves into the intricacies of estrogen synthesis and metabolism, the diverse signaling pathways mediated by estrogen receptors, and the profound implications of estrogen dysregulation in various diseases, including but not limited to breast cancer, osteoporosis, cardiovascular disease, neurodegenerative disorders, and autoimmune conditions. We will also explore the complex interplay between estrogen and environmental factors, including alcohol consumption, that can disrupt hormonal balance and contribute to disease pathogenesis. This report aims to provide an in-depth understanding of estrogen biology, its significance in maintaining overall health, and its involvement in the development of numerous diseases, catering to an expert audience familiar with the field.

Many thanks to our sponsor Maggie who helped us prepare this research report.

1. Introduction

Estrogens, a class of steroid hormones, are critical regulators of numerous physiological processes. Historically, their primary association has been with the development and maintenance of female secondary sexual characteristics and the regulation of the menstrual cycle. However, it is now well-established that estrogens exert pleiotropic effects across diverse tissues and organs in both females and males. These effects are mediated through complex signaling pathways involving estrogen receptors (ERs), both nuclear and membrane-bound, and their interactions with various co-regulators. Given the widespread influence of estrogens, their dysregulation is implicated in a variety of diseases, ranging from reproductive disorders and cancers to cardiovascular diseases and neurodegenerative conditions. This review provides a comprehensive overview of estrogen biology, focusing on its synthesis, metabolism, signaling mechanisms, and implications in health and disease.

Many thanks to our sponsor Maggie who helped us prepare this research report.

2. Estrogen Synthesis and Metabolism

The principal estrogens in humans are estrone (E1), estradiol (E2), and estriol (E3). Estradiol (E2) is the most potent and abundant estrogen in premenopausal women, while estrone (E1) becomes the predominant estrogen after menopause. Estriol (E3) is primarily produced during pregnancy. The biosynthesis of estrogens is a complex process involving multiple enzymatic steps, primarily occurring in the ovaries in females and the testes in males, with smaller contributions from the adrenal glands and peripheral tissues. The key enzyme in estrogen biosynthesis is aromatase (CYP19A1), which converts androgens (androstenedione and testosterone) into estrogens (estrone and estradiol, respectively).

The synthesis pathway begins with cholesterol and proceeds through a series of enzymatic conversions, primarily within the mitochondria and endoplasmic reticulum. Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. LH stimulates the theca cells in the ovaries to produce androgens, while FSH stimulates the granulosa cells to express aromatase, converting these androgens into estrogens. In males, LH stimulates Leydig cells in the testes to produce testosterone, a portion of which is converted to estradiol by aromatase. The activity of aromatase is tightly regulated by various factors, including age, body mass index (BMI), and the presence of certain diseases.

Estrogen metabolism primarily occurs in the liver, where estrogens are hydroxylated, conjugated with glucuronic acid or sulfate, and then excreted in the urine or bile. The cytochrome P450 (CYP) enzyme family plays a crucial role in estrogen metabolism. Specifically, CYP1A2, CYP3A4, and CYP2C9 are involved in the hydroxylation of estrogens at various positions, leading to the formation of different metabolites with varying estrogenic activities. The balance between the production of active estrogens and their inactive metabolites is crucial for maintaining hormonal homeostasis. Dysregulation of estrogen metabolism, for example, through genetic polymorphisms in CYP genes or exposure to environmental toxins, can significantly alter estrogen levels and increase the risk of estrogen-related diseases.

Many thanks to our sponsor Maggie who helped us prepare this research report.

3. Estrogen Receptor Signaling Pathways

Estrogens exert their effects primarily through binding to estrogen receptors (ERs), which are members of the nuclear receptor superfamily. Two main subtypes of ERs have been identified: ERα (ESR1) and ERβ (ESR2). These receptors are ligand-activated transcription factors that regulate the expression of target genes. While both ERα and ERβ bind to estrogens with similar affinity, they differ in their tissue distribution, ligand selectivity, and downstream signaling pathways.

3.1. Classical Genomic Signaling

The classical mechanism of estrogen action involves the binding of estrogen to ERs in the cytoplasm or nucleus. Upon ligand binding, the ER undergoes a conformational change, dimerizes, and translocates to the nucleus (if it hasn’t already). The ER dimer then binds to specific DNA sequences called estrogen response elements (EREs) located in the promoter regions of target genes. This binding recruits co-activators or co-repressors, which modulate chromatin structure and regulate gene transcription. The specific genes regulated by ERs vary depending on the cell type and the context of other signaling pathways. ERα and ERβ can form both homodimers (ERα-ERα or ERβ-ERβ) and heterodimers (ERα-ERβ), each with distinct transcriptional activities.

3.2. Non-Genomic Signaling

In addition to the classical genomic signaling pathway, estrogens can also exert rapid, non-genomic effects through membrane-associated ERs. These membrane ERs are typically localized in caveolae and are coupled to various signaling molecules, including G proteins, receptor tyrosine kinases (RTKs), and ion channels. Upon estrogen binding, membrane ERs can activate signaling cascades such as the MAPK/ERK, PI3K/Akt, and calcium signaling pathways. These non-genomic effects can modulate cellular processes such as cell proliferation, survival, and migration independently of gene transcription. Furthermore, some ERs are expressed within the mitochondria, influencing mitochondrial function and energy production.

3.3. Ligand-Independent Activation

ERs can also be activated in a ligand-independent manner by growth factors, cytokines, and other signaling molecules. For example, growth factor receptors such as EGFR and HER2 can activate intracellular signaling pathways that phosphorylate ERs, leading to their activation even in the absence of estrogen. This ligand-independent activation of ERs can contribute to endocrine resistance in breast cancer cells.

Many thanks to our sponsor Maggie who helped us prepare this research report.

4. Estrogen and Breast Cancer

The role of estrogen in breast cancer development is one of the most extensively studied areas of estrogen research. Estrogen promotes the proliferation and survival of breast epithelial cells, and prolonged exposure to estrogen is a major risk factor for breast cancer. Approximately 70% of breast cancers are estrogen receptor-positive (ER+), meaning that their growth is driven by estrogen signaling.

4.1. Mechanisms of Estrogen-Driven Breast Cancer

Estrogen promotes breast cancer development through multiple mechanisms. First, estrogen directly stimulates the proliferation of ER+ breast cancer cells by activating the classical genomic signaling pathway. This leads to the upregulation of genes involved in cell cycle progression and DNA replication. Second, estrogen can promote the survival of breast cancer cells by activating the PI3K/Akt pathway, which inhibits apoptosis. Third, estrogen can stimulate angiogenesis, the formation of new blood vessels, which is essential for tumor growth and metastasis. Fourth, estrogen can promote inflammation in the breast microenvironment, which can further enhance tumor growth and metastasis. It’s important to note that the specific effects of estrogen on breast cancer cells depend on the relative levels of ERα and ERβ, as well as the presence of other signaling molecules and co-regulators.

4.2. Endocrine Therapies for Breast Cancer

Given the critical role of estrogen in breast cancer development, endocrine therapies that block estrogen signaling are widely used for the treatment of ER+ breast cancer. These therapies include selective estrogen receptor modulators (SERMs), such as tamoxifen, which bind to ERs and act as antagonists in breast tissue. Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, block the synthesis of estrogen by inhibiting aromatase. Selective estrogen receptor degraders (SERDs), such as fulvestrant, bind to ERs and promote their degradation. While endocrine therapies are highly effective in treating ER+ breast cancer, many patients eventually develop resistance. Mechanisms of resistance include mutations in the ER gene, upregulation of growth factor signaling pathways, and activation of alternative survival pathways.

4.3. Alcohol and Estrogen in Breast Cancer

As the context for this review is the impact of alcohol, it’s critical to elaborate on this relationship. Alcohol consumption has been consistently linked to an increased risk of breast cancer. The precise mechanisms underlying this association are complex and multifactorial, but one prominent mechanism involves the disruption of hormone levels, particularly estrogen. Alcohol can increase estrogen levels by several means. It inhibits the liver’s ability to metabolize estrogen, leading to higher circulating estrogen concentrations. It also promotes the conversion of androgens to estrogens via increased aromatase activity. In addition, alcohol can impair the function of the hypothalamic-pituitary-ovarian (HPO) axis, further disrupting hormonal balance. Furthermore, alcohol can interact with estrogen signaling pathways at the cellular level, potentially enhancing the proliferative effects of estrogen on breast cancer cells. The increased estrogen levels resulting from alcohol consumption contribute to the increased risk of ER+ breast cancer. This interaction highlights the importance of considering lifestyle factors, such as alcohol intake, in the context of estrogen-related diseases.

Many thanks to our sponsor Maggie who helped us prepare this research report.

5. Estrogen and Other Conditions

Beyond breast cancer, estrogen plays a significant role in a wide range of other conditions, affecting various organ systems.

5.1. Osteoporosis

Estrogen is essential for maintaining bone density and preventing osteoporosis, a condition characterized by reduced bone mass and increased risk of fractures. Estrogen promotes bone formation by stimulating osteoblast activity and inhibiting bone resorption by suppressing osteoclast activity. The decline in estrogen levels after menopause leads to accelerated bone loss and an increased risk of osteoporotic fractures. Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) were once commonly used to prevent and treat osteoporosis, but concerns about potential side effects, such as increased risk of breast cancer and cardiovascular disease, have led to a more cautious approach. Selective estrogen receptor modulators (SERMs) like raloxifene are now commonly used as an alternative to ERT/HRT, as they provide estrogen-like benefits on bone without increasing the risk of breast cancer.

5.2. Cardiovascular Disease

The role of estrogen in cardiovascular disease is complex and somewhat controversial. Observational studies initially suggested that ERT/HRT could protect against cardiovascular disease in postmenopausal women. However, subsequent randomized controlled trials, such as the Women’s Health Initiative (WHI), showed that ERT/HRT did not provide cardiovascular benefits and may even increase the risk of stroke and venous thromboembolism. These conflicting findings highlight the importance of considering the timing of estrogen therapy, as it may have different effects depending on the stage of life and the presence of other risk factors. Estrogen can affect cardiovascular function through multiple mechanisms, including regulating lipid metabolism, improving endothelial function, and reducing inflammation. However, the specific effects of estrogen on cardiovascular disease are influenced by the type of estrogen, the route of administration, and the individual’s genetic background.

5.3. Neurodegenerative Disorders

Estrogen has neuroprotective effects and may play a role in preventing or delaying the onset of neurodegenerative disorders such as Alzheimer’s disease (AD). Estrogen can enhance neuronal survival, promote synaptic plasticity, and reduce oxidative stress and inflammation in the brain. The decline in estrogen levels after menopause may contribute to the increased risk of AD in women. Some studies have suggested that ERT/HRT may improve cognitive function and reduce the risk of AD, but the evidence is inconsistent. The optimal timing and duration of estrogen therapy for neuroprotection remain unclear. Research suggests that estrogen’s role in protecting cognitive function may be linked to its effects on the cholinergic system, promoting acetylcholine production and receptor sensitivity.

5.4. Autoimmune Diseases

Estrogen can modulate the immune system and influence the development and progression of autoimmune diseases. Autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), are more common in women than in men, suggesting a role for sex hormones in their pathogenesis. Estrogen can enhance the activity of B cells and T helper cells, leading to increased antibody production and inflammation. Conversely, estrogen can also suppress the activity of regulatory T cells, which are important for maintaining immune tolerance. The effects of estrogen on autoimmune diseases are complex and depend on the specific disease, the dose and timing of estrogen exposure, and the individual’s genetic background. Research indicates that estrogen can influence the balance between pro-inflammatory and anti-inflammatory cytokines, tipping the scale towards increased inflammation in some autoimmune conditions.

5.5 Menopause and Cognitive function

Estrogen plays a crucial role in cognitive function, and the hormonal changes associated with menopause can significantly impact a woman’s cognitive abilities. During menopause, the decline in estrogen levels can lead to symptoms such as memory problems, difficulty concentrating, and mood changes. Estrogen influences various aspects of cognitive function, including verbal memory, working memory, and executive functions. It supports neuronal survival, synaptic plasticity, and neurotransmitter systems that are essential for optimal brain function. Estrogen receptors are widely distributed throughout the brain, particularly in regions associated with learning and memory, such as the hippocampus and prefrontal cortex. Estrogen replacement therapy (ERT) has been shown to improve cognitive performance in some postmenopausal women, particularly when initiated early in menopause. However, the effects of ERT on cognitive function can vary depending on the individual, the dose and duration of treatment, and the specific cognitive domain being assessed. Further research is needed to fully understand the long-term effects of estrogen therapy on cognitive aging and the prevention of cognitive decline.

Many thanks to our sponsor Maggie who helped us prepare this research report.

6. Future Directions

Research on estrogen biology continues to be a vibrant and rapidly evolving field. Future research directions include: (1) Elucidating the precise mechanisms by which estrogen mediates its effects in different tissues and organs; (2) Identifying novel estrogen receptor subtypes and signaling pathways; (3) Developing more selective estrogen receptor modulators (SERMs) with improved efficacy and safety profiles; (4) Investigating the role of estrogen in the pathogenesis of complex diseases such as cancer, cardiovascular disease, and neurodegenerative disorders; (5) Exploring the potential of estrogen-based therapies for preventing and treating these diseases. Furthermore, a deeper understanding of the interplay between estrogen and environmental factors, such as diet, exercise, and exposure to endocrine disruptors, is crucial for developing effective strategies to maintain hormonal balance and prevent estrogen-related diseases. Single-cell sequencing and spatial transcriptomics are emerging technologies that can provide unprecedented insights into the heterogeneity of estrogen signaling in different cell types and tissues. These advanced techniques will enable researchers to identify novel targets for therapeutic intervention and develop personalized approaches to estrogen-related diseases.

Many thanks to our sponsor Maggie who helped us prepare this research report.

7. Conclusion

Estrogens are essential hormones that play a critical role in a wide range of physiological processes. Their actions are mediated through complex signaling pathways involving estrogen receptors and various co-regulators. Dysregulation of estrogen levels or signaling is implicated in a variety of diseases, including breast cancer, osteoporosis, cardiovascular disease, neurodegenerative disorders, and autoimmune conditions. A thorough understanding of estrogen biology is crucial for developing effective strategies to prevent and treat these diseases. Future research efforts should focus on elucidating the precise mechanisms of estrogen action, identifying novel therapeutic targets, and developing personalized approaches to estrogen-related diseases. The complex interplay between estrogen and environmental factors, lifestyle, and genetic predisposition warrants further investigation to better understand the pathogenesis of diseases linked to this vital hormone.

Many thanks to our sponsor Maggie who helped us prepare this research report.

References

• Anderson, B. D., & Hickey, M. (2017). The pharmacology of estrogen and progestogen therapy in postmenopause. Climacteric, 20(3), 205-215.
• Björnström, L., & Sjöberg, M. (2005). Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Molecular Endocrinology, 19(4), 833-842.
• Chen, C. Q., & Zhou, H. M. (2020). Estrogen and brain aging: multiple mechanisms underlying neuroprotection. Aging and Disease, 11(2), 279.
• Cleary, M. P., & Grossmann, M. E. (2009). Minireview: mechanisms by which obesity increases breast cancer risk. Endocrinology, 150(6), 2537-2542.
• Davis, S. R., Baber, R. J., Panay, N., et al. (2016). Global Consensus Statement on Menopausal Hormone Therapy. Climacteric, 19(2), 87-102.
• Deroo, B. J., & Korach, K. S. (2006). Estrogen receptors and human disease. Journal of Clinical Investigation, 116(3), 561-570.
• Endogenous Hormones and Breast Cancer Collaborative Group. (2003). Alcohol, endogenous sex hormones, and breast cancer: a systematic review and meta-analysis. Cancer Causes & Control, 14(8), 781-791.
• Hall, J. E. (2014). Neuroendocrine effects of menopause. Maturitas, 78(2), 86-90.
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2007). Alcohol consumption and ethyl carbamate. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 96, 3-1383.
• Klinge, C. M. (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids Research, 29(14), 2905-2919.
• Lobo, R. A. (2017). Hormone therapy: benefits versus risks. Fertility and Sterility, 107(1), 1-8.
• Mauvais-Jarvis, F., Clegg, D. J., & Wagner, K. U. (2013). Estrogen and androgen signaling in the brain: impact on energy balance and metabolism. Endocrine Reviews, 34(2), 269-297.
• Nelson, H. D., Haney, E. M., Griffin, J., et al. (2002). Postmenopausal hormone replacement therapy: scientific review. JAMA, 288(7), 872-881.
• O’Mara, B. A., Weberpals, J. I., Villeneuve, P. J., & Parent, M. É. (2011). Alcohol consumption, cigarette smoking, and breast cancer risk: a Canadian population-based case–control study. Breast Cancer Research and Treatment, 125(3), 831-840.
• Prokai, L., & Simpkins, J. W. (2005). Neuroprotective mechanisms triggered by estrogen in the brain. Progress in Neurobiology, 75(1), 35-59.
• Russo, J., & Russo, I. H. (2006). The role of estrogen in the initiation and progression of breast cancer. Journal of Mammary Gland Biology and Neoplasia, 11(4), 293-306.
• Simpson, E. R. (2003). Sources of estrogen and their importance. Fertility and Sterility, 79(3), 3-14.
• Stevenson, J. C., Crook, D., Ganger, K. F., et al. (1992). Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet, 340(8817), 265-269.
• Yue, W., Wang, X., Li, Y., Fan, P., Holloway, A. C., & Trudeau, V. L. (2013). Mechanisms of disease: estrogen synthesis, signaling, and function in breast cancer. Frontiers in Endocrinology, 4, 127.
• Zoeller, R. T., Brown, T. R., Doan, L. L., Gore, A. C., Guillette Jr, L. J., Hayes, T. B., … & Woodruff, T. J. (2012). Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrine Reviews, 33(1), 78-95.